Abstract
Objective Research suggest insomnia possibly decrease immune function and therby increase risk of infections. Insomnia is the most common sleeping disorder and is potentially treatable and preventable. As infections can lead to severe illness, finding potentially preventable risk factor is of outmost importance. We wanted to determine whether insomnia is a risk factor for the severe infectious disease sepsis.
Methods We used two sample mendelian randomization (MR) as our method investigate the causal association between insomnia and risk of sepsis. We obtained a total of 203 genetic variants associated with insomnia, from the UK Biobank and 23andMe genome-wide association studies (GWAS), derived from 1,3 million subjects. From the UK Biobank GWAS 10,154 sepsis cases were extracted, and 452,764 were controls.
Results Insomnia was associated with a 7% (95% CI 2–13%, P=0.01) increased odds of genetically-predicted sepsis.
Conclusions Our results provide evidence that suggests insomnia is causally associated with an increased risk of sepsis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available human data that were originally located at: UK biobank and 23andMe.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at
https://research.23andme.com/dataset-access/
https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access
